Association between level of hepatitis d virus RNA at week 24 of pegylated interferon therapy and outcome

Simple item page
dc.contributor.authorKeskin, Onur
dc.contributor.authorWedemeyer, Heiner
dc.contributor.authorTüzün, Ali
dc.contributor.authorZachou, Kalliopi
dc.contributor.authorDeda, Xheni
dc.contributor.authorDalekos, George N.
dc.contributor.authorHeidrich, Benjamin
dc.contributor.authorPehlivan, Selcen
dc.contributor.authorZeuzem, Stefan
dc.contributor.authorYalçın, Kendal
dc.contributor.authorTabak, Fehmi
dc.contributor.authorİdilman, Ramazan
dc.contributor.authorBozkaya, Hakan
dc.contributor.authorManns, Michael
dc.contributor.authorYurdaydın, Cihan
dc.contributor.buuauthorGürel, Selim
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji Anabilim Dalı.tr_TR
dc.contributor.scopusid7003706434tr_TR
dc.date.accessioned2022-06-13T07:27:17Z
dc.date.available2022-06-13T07:27:17Z
dc.date.issued2015-12
dc.description.abstractBACKGROUND & AIMS: Interferon is the only effective treatment for chronic hepatitis D virus (HDV) infection. No rules have been set for stopping treatment based on viral kinetics. We analyzed data from an international study of hepatitis D treatment to identify factors associated with outcomes of pegylated interferon treatment, with and without adefovir. METHODS: We analyzed data from the Hep-Net-International Delta Hepatitis Intervention Trial on 50 patients with compensated liver disease who tested positive for anti-HDV and HDV RNA. Subjects received pegylated interferon alpha 2a, with adefovir or placebo, or only adefovir, for 48 weeks. Twenty-four weeks after treatment ended, 41 patients were evaluated for levels of HDV RNA and DNA, liver enzymes, and hepatitis B surface antigen (HBsAg); liver biopsy specimens were analyzed for fibrosis. Response to therapy was defined as end-of-treatment response or post-treatment week 24 virologic response. In both cases virologic response was associated with undetectable HDV RNA levels. Patients with less than a 1 log decrease in HDV RNA at the end of treatment were considered null responders. RESULTS: Based on univariate and multivariate analysis, the level of HDV RNA at week 24 of treatment was associated more strongly with response to therapy than other factors analyzed. The level of HBsAg at week 24 of treatment was associated with a response to therapy only in univariate analysis. Lack of HDV RNA at week 24 of treatment, or end of treatment, identified responders with positive predicted values of 71% and 100%, respectively. At 24 weeks after treatment, a decrease in HDV RNA level of less than 1 log, combined with no decrease in HBsAg level, identified null responders with a positive predictive value of 83%. A decrease in HDV RNA level of more than 2 log at week 24 of treatment identified null responders with a negative predictive value of 95%. CONCLUSIONS: Based on an analysis of data from a large clinical trial, the level of HDV RNA at week 24 of treatment with pegylated interferon, with or without adefovir for 48 weeks, can identify patients who will test negative for HDV RNA 24 weeks after the end of treatment. This information can be used to help physicians manage patients receiving therapy for chronic hepatitis D.en_US
dc.description.sponsorshipHep-Net Germany (German Ministry for Education and Research, BMBF-Forderkennzeichen)en_US
dc.description.sponsorshipRoche Turkeyen_US
dc.identifier.citationKeskin, O. vd. (2015). "Association between level of hepatitis d virus RNA at week 24 of pegylated interferon therapy and outcome". Clinical Gastroenterology and Hepatology, 13(13), 2342-2349.en_US
dc.identifier.endpage2349tr_TR
dc.identifier.issn1542-3565
dc.identifier.issue13tr_TR
dc.identifier.pubmed26044319tr_TR
dc.identifier.scopus2-s2.0-84947244327tr_TR
dc.identifier.startpage2342tr_TR
dc.identifier.urihttps://doi.org/10.1016/j.cgh.2015.05.029
dc.identifier.urihttps://www.sciencedirect.com/science/article/abs/pii/S1542356515007648
dc.identifier.urihttp://hdl.handle.net/11452/27085
dc.identifier.volume13tr_TR
dc.identifier.wos000365191300025tr_TR
dc.indexed.pubmedPubMeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.collaborationYurt içitr_TR
dc.relation.collaborationYurt dışıtr_TR
dc.relation.collaborationSanayitr_TR
dc.relation.journalClinical Gastroenterology and Hepatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChronic delta hepatitisen_US
dc.subjectOn-treatment HDV RNAen_US
dc.subjectPegylated interferon treatmenten_US
dc.subjectTreatment outcome predictionen_US
dc.subjectChronic delta-hepatitisen_US
dc.subjectPeginterferon alpha-2aen_US
dc.subjectKineticsen_US
dc.subjectInterleukin-28ben_US
dc.subjectPolymorphismsen_US
dc.subjectRibavirinen_US
dc.subjectEfficacyen_US
dc.subjectHbsagen_US
dc.subjectDrugen_US
dc.subjectGastroenterology & hepatologyen_US
dc.subject.emtreeAdefoviren_US
dc.subject.emtreeAdefovir dipivoxilen_US
dc.subject.emtreeHepatitis B surface antigenen_US
dc.subject.emtreeLiver enzymeen_US
dc.subject.emtreePeginterferon alpha2aen_US
dc.subject.emtreePlaceboen_US
dc.subject.emtreeVirus DNAen_US
dc.subject.emtreeVirus RNAen_US
dc.subject.emtreeAdenineen_US
dc.subject.emtreeAlpha interferonen_US
dc.subject.emtreeAminotransferaseen_US
dc.subject.emtreeAntivirus agenten_US
dc.subject.emtreeHepatitis B surface antigenen_US
dc.subject.emtreeMacrogol derivativeen_US
dc.subject.emtreePeginterferon alpha2aen_US
dc.subject.emtreePhosphonic acid derivativeen_US
dc.subject.emtreePlaceboen_US
dc.subject.emtreeRecombinant proteinen_US
dc.subject.emtreeVirus DNAen_US
dc.subject.emtreeVirus RNAen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeClinical articleen_US
dc.subject.emtreeCombination chemotherapyen_US
dc.subject.emtreeControlled clinical trialen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeDelta agent hepatitisen_US
dc.subject.emtreeDisease associationen_US
dc.subject.emtreeDrug efficacyen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeFollow upen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeHuman tissueen_US
dc.subject.emtreeLiver biopsyen_US
dc.subject.emtreeLiver fibrosisen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeMonotherapyen_US
dc.subject.emtreeNonhumanen_US
dc.subject.emtreeOutcome assessmenten_US
dc.subject.emtreePredictive valueen_US
dc.subject.emtreeTreatment durationen_US
dc.subject.emtreeTreatment responseen_US
dc.subject.emtreeAnalogs and derivativesen_US
dc.subject.emtreeBiopsyen_US
dc.subject.emtreeBlooden_US
dc.subject.emtreeClinical trialen_US
dc.subject.emtreeGeneticsen_US
dc.subject.emtreeHepatitis D, Chronicen_US
dc.subject.emtreeHepatitis delta virusen_US
dc.subject.emtreeIsolation and purificationen_US
dc.subject.emtreeLiver cirrhosisen_US
dc.subject.emtreeMiddle ageden_US
dc.subject.emtreePathologyen_US
dc.subject.emtreeTreatment outcomeen_US
dc.subject.emtreeVirus loaden_US
dc.subject.meshAdenineen_US
dc.subject.meshAdulten_US
dc.subject.meshAntiviral agentsen_US
dc.subject.meshBiopsyen_US
dc.subject.meshDNA, viralen_US
dc.subject.meshFemaleen_US
dc.subject.meshHepatitis B surface antigensen_US
dc.subject.meshHepatitis D, chronicen_US
dc.subject.meshHepatitis delta virusen_US
dc.subject.meshHumansen_US
dc.subject.meshInterferon-alphaen_US
dc.subject.meshLiver cirrhosistr_TR
dc.subject.meshMaleen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshOrganophosphonatesen_US
dc.subject.meshPlacebosen_US
dc.subject.meshPolyethylene glycolsen_US
dc.subject.meshRecombinant proteinsen_US
dc.subject.meshRNA, viralen_US
dc.subject.meshTransaminasesen_US
dc.subject.meshTreatment outcomeen_US
dc.subject.meshViral loaden_US
dc.subject.scopusHepatitis Delta Virus; Chronic Hepatitis D; Hepatitis Ben_US
dc.subject.wosGastroenterology & hepatologyen_US
dc.titleAssociation between level of hepatitis d virus RNA at week 24 of pegylated interferon therapy and outcomeen_US
dc.typeArticle
dc.wos.quartileQ1en_US

Files

License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
Scopus